Vertex Pharmaceuticals VRTX Product revenues, net — Product revenues, net

Other product segments

Similar metrics at other companies

INSMBRINSUPRI — Product revenues, net

$309.17M—

COLLAzstarys — Product revenues, net

$12.91M—

COLLBelbuca — Product revenues, net

$57.67M+9.6%

COLLSymproic — Product revenues, net

$3.02M-18.9%

INSMInternational — Product revenues, net

$46.75M+20.7%

INSMUS — Product revenues, net

$378.74M+451%

FAQ

What is Vertex Pharmaceuticals's product revenues, net — product revenues, net?

Vertex Pharmaceuticals (VRTX) reported product revenues, net — product revenues, net of $3.33B in Q2 2026.

How has Vertex Pharmaceuticals's product revenues, net — product revenues, net changed year-over-year?

Vertex Pharmaceuticals's product revenues, net — product revenues, net increased by 13.2% year-over-year, from $2.94B to $3.33B.

What is the long-term trend for Vertex Pharmaceuticals's product revenues, net — product revenues, net?

Over 4 years (2021 to 2025), Vertex Pharmaceuticals's product revenues, net — product revenues, net has grown at a 12.1% compound annual growth rate (CAGR), from $7.57B to $11.97B.

What does product revenues, net — product revenues, net mean?

This metric represents the total net revenue generated from the sale of pharmaceutical products after accounting for returns, discounts, rebates, and other sales allowances. It serves as the primary indicator of the company's commercial success in delivering its therapeutic portfolio to patients and healthcare providers. This figure reflects the core top-line performance of the company's marketed drug assets.